Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Testicular Cancer
Do you cap cisplatin dose in obese patients undergoing chemotherapy in germ cell tumors?
Do you cap BSA at 2 or 2.2 for such patients to prevent Cisplatin neuropathy and CKD?
Related Questions
Would you recommend VIP x 4 cycles over EP x 4 cycles in a patient with good risk Stage IIIB seminoma but an elevated LDH over 5x upper limit of normal with a 20 pack year smoking history?
What treatment would you offer a patient with Down syndrome and stage IIA seminoma?
Is there a preferred chemotherapy regimen for chemo-mobilization prior to HDCT for a patient with NSGCT with prior BEP and TIP?
If a patient diagnosed with seminoma after orchiectomy has margin positive disease noted in the spermatic cord and no overt metastasis on imaging and normal tumor markers, how should this patient be staged?
What is your preferred choice of therapy for first-line treatment of a patient with good, intermediate, or poor risk stage III nonseminomatous germ cell tumor if the patient is truly cisplatin-ineligible?
Which patients with prostate cancer do you consider to be good candidates for salvage local treatment after radiation therapy?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA > 3000 but no visceral or bone metastases?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
Is it safe to administer cabazitaxel to a patient with mCRPC who developed grade 3 pneumonitis from docetaxel?